Clinical distribution and drug resistance evolution of Acinetobacter baumannii in Zhejiang Xiaoshan Hospital, 2008-2013

Objective To understand the clinical distribution and drug resistance of Acinetobacter baumannii in hospitals and provide references for the clinical diagnosis and treatment/prevention of nosocomial infection. Methods Retrospective statistical analysis was performed on the clinical distribution and drug resistance results of A. baumannii isolated from patient samples in our hospital from January 2008 to December 2013 by using WHONET 5.6. K-B methods was used to detect drug susceptibility, VITEK-2 COMPACT automated microbial analysis system was used for bacteria identification of bacteria and drug, resistant rates between ICU strains and non-ICU strains were compared. Results A total of 776 A. baumannii strains were isolated in our hospital, in which 655 were from respiratory tract samples (84.4%), and 219 strains were from ICU (28.2%). Compared with 2008, the resistant rates to ceftazidime, imipenem, gentamicin decreased in 2013, but the resistant rates to ampicillin, cefuroxime, aztreonam and cefoxitin remained high (89.4%), the resistant rates to cefoperazone/sulbactam was low (16.1%). The resistant rates to imipenem and meropenem were 24.8% and 27.7%; The resistant rates had significant difference between ICU strains and non ICU strains (P0.05). Conclusion A. baumannii, which is widely distributed in different clinical samples in hospitals, is an important non-fermentative bacteria causing nosocomial infection. It is necessary to pay more attention to A. baumannii infection in clinical departments especially in ICU. Cefoperazone/sulbactam can be used as the first choice for the treatment of A. baumannii infection. Strict management of nosocomial infection and standard antibiotic therapy can reduce the spread of resistant strains and prevent the development of drug resistance.